ABEO Abeona Therapeutics Inc

Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced it will host its 2nd R&D Day event for the institutional investment community in New York on Thursday, December 6, 2018. The formal program is scheduled to begin at 8:45 am ET and conclude at 1:00 pm ET. A live webcast of the event will be available on the investor relations section of Company’s website at www.abeonatherapeutics.com. The program will include presentations and panel discussions featuring senior management, clinical investigators and key opinion leaders on current topics in gene therapy.

About AbeonaAbeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.

Investor Contact:Christine Silverstein SVP, Finance & Investor Relations Abeona Therapeutics Inc. +1 (646) 813-4707 csilverstein@abeonatherapeutics.com

Media Contact:Scott Santiamo Director, Corporate Communications Abeona Therapeutics Inc. +1 (718) 344-5843 ssantiamo@abeonatherapeutics.com